
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. demonstrated significant growth in its Signatera clinical units, reporting approximately 181,000 units for the quarter, which represents an increase of about 20,000 units sequentially and exceeds earlier estimates. The company has also raised its gross margin guidance to a range of 61% to 64%, indicating improved average selling price trends and expectations for increased adoption of the Signatera test among first-time patients. These positive developments suggest a robust demand for Natera's diagnostic offerings, contributing to a favorable outlook for the company's financial performance.
Bears say
Natera Inc. is facing significant challenges due to its ongoing cash burn and lack of profitability, which raises concerns about its financial sustainability. The company relies heavily on reimbursement for its diagnostic tests, and any inability to secure such reimbursement or a reduction in reimbursement rates could severely impact its financial results. Additionally, concerning findings regarding the outcomes of transplant patients could hinder the adoption of its Prospera test and likely dampen overall market confidence in the company's product efficacy.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares